Oxford Biomedica Plc Announces Interim Results For Six Months Ended 30 June 2019

  • Sep 04, 2019 BST
  • Team Kalkine

Revenues declined 9% year over year to £32.1 million in H1 2019 while operating EBITDA was a loss of £1.4 million. Cash generated from operations in H1 2019 was £1.3 million compared to £18.3 million in the year-ago period. Cash at 30 June 2019 was £26.1 million compared to £32.2 million at 31 December 2018.

The company entered into an R&D collaboration with Santen Pharmaceutical Co Ltd for a retinal disease during the reported period.

On 4th September 2019, at the time of writing, GMT 11:51 AM, OXB shares were quoted at GBX 623, down 16 points or 2.50% over the previous day closing price.

With Bank of England reducing the interest rates to a historic low level, the spotlight is back on diverse investment opportunities. 

Amidst this, are you getting worried about these falling interest rates and wondering where to put your money?

Well! Team Kalkine has a solution for you. You still can earn a relatively stable income by putting money in the dividend-paying stocks.

We think it is the perfect time when you should start accumulating selective dividend stocks to beat the low-interest rates, while we provide a tailored offering in view of valuable stock opportunities and any dividend cut backs to be considered amid scenarios including a prolonged market meltdown.

To know more about these dividend stocks, click here

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK